Determining candidates for peanut oral immunotherapy: Insights from the RAMSES trial

Affiliations

¹ Division of Allergy and Immunology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: dattar2@chop.edu.

Editorial

Rahul Datta. Ann Allergy Asthma Immunol. 2022 Dec.

. 2022 Dec;129(6):661-662.

doi: 10.1016/j.anai.2022.09.010.

¹ Division of Allergy and Immunology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: dattar2@chop.edu.

No abstract available

Comment on

Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Ciaccio C, Goldsobel AB, Anagnostou A, Beyer K, Casale TB, Deschildre A, Fernández-Rivas M, Hourihane JO, Krawiec M, Lieberman J, Scurlock AM, Vickery BP, Smith A, Tilles SA, Adelman DC, Brown KR; RAMSES (ARC007) and ARC011 Study Groups:. Ciaccio C, et al. Ann Allergy Asthma Immunol. 2022 Dec;129(6):758-768.e4. doi: 10.1016/j.anai.2022.07.033. Epub 2022 Aug 13. Ann Allergy Asthma Immunol. 2022. PMID: 35973655 Clinical Trial.